Seagen has been granted a patent for humanized antibodies that specifically bind to BCMA. These antibodies can be used for the treatment and diagnosis of various cancers and immune disorders, as well as for detecting BCMA. The patent also includes a method for treating cancer by administering an antibody or binding fragment that binds to human BCMA. The antibody or binding fragment must have specific amino acid sequences in the heavy and light chain variable regions. GlobalData’s report on Seagen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Seagen, Nanoparticle drug conjugates was a key innovation area identified from patents. Seagen's grant share as of September 2023 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
Humanized antibodies for treating cancer expressing bcma
A recently granted patent (Publication Number: US11767365B2) discloses a method for treating cancer that expresses human B-cell maturation antigen (BCMA). The method involves administering an effective amount of an antibody or binding fragment that binds to human BCMA. The antibody or binding fragment consists of a mature heavy chain variable region and a mature light chain variable region. The mature heavy chain variable region includes complementarity determining regions (CDRs) with specific amino acid sequences, while the mature light chain variable region also includes CDRs with specific amino acid sequences.
The method further specifies that the mature heavy chain variable region can be fused to a heavy chain constant region, and the mature light chain variable region can be fused to a light chain constant region. The heavy chain constant region can be a mutant form of a natural human constant region with reduced binding to an Fc? receptor. Additionally, the heavy chain constant region can be of the immunoglobulin G1 (IgG1) isotype. The specific amino acid sequences for the heavy chain constant region and the light chain constant region are provided.
The antibody or binding fragment can be non-fucosylated and can also be an antibody binding fragment, such as a Fab, a Fab', or a F(ab')2. Furthermore, the antibody can be a humanized antibody.
The disclosed method is applicable to the treatment of hematological cancers, including myeloma, leukemia, lymphoma, myelodysplastic syndromes (MDS), myeloproliferative syndromes (MPS), Waldenström's macroglobulinemia, and Burkett's lymphoma. The method can be used to treat multiple myeloma, non-Hodgkin's lymphoma (NHL), and Hodgkin's lymphoma.
The patent also describes variations of the method, including the use of different amino acid sequences for the mature heavy chain variable region and the mature light chain variable region. Additionally, a composition comprising a plurality of antibodies or binding fragments that bind to human BCMA is disclosed. The composition can have a reduced percentage of fucosylated antibodies or binding fragments.
Overall, this granted patent provides a method for treating cancer expressing BCMA using specific antibodies or binding fragments, offering potential advancements in the field of cancer treatment, particularly for hematological cancers.
To know more about GlobalData’s detailed insights on Seagen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
